Broker Revenue Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher

Shareholders in Wave Life Sciences Ltd. (NASDAQ:WVE) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The analysts have sharply increased their revenue numbers, with a view that Wave Life Sciences will make substantially more sales than they'd previously expected.

Following the latest upgrade, the current consensus, from the eight analysts covering Wave Life Sciences, is for revenues of US$70m in 2024, which would reflect a substantial 37% reduction in Wave Life Sciences' sales over the past 12 months. Before the latest update, the analysts were foreseeing US$62m of revenue in 2024. The consensus has definitely become more optimistic, showing a solid increase in revenue forecasts.

View our latest analysis for Wave Life Sciences

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 60% by the end of 2024. This indicates a significant reduction from annual growth of 43% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 10% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Wave Life Sciences is expected to lag the wider industry.

The Bottom Line

The most important thing to take away from this upgrade is that analysts lifted their revenue estimates for this year. They also expect company revenue to perform worse than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Wave Life Sciences.

Unsatisfied? We have analyst estimates for Wave Life Sciences going out to 2026, and you can see them free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.